Results of a small Phase 2 study show that the four-drug combination therapy of Revlimid, Velcade, Doxil, and dexamethasone may be an effective and tolerable treatment option for relapsed and refractory multiple myeloma patients.

According to the study investigators, the four-drug regimen compares favorably to the three-drug combination without Revlimid in that it improves response rates without a significant increase in side effects.

The investigators recommend that future trials further investigate the number and specific types of previous treatments to identify those in which the Revlimid, Velcade, Doxil, and dexamethasone combination may …